natgillin/translations-raw huggingface dataset:
As a consequence, no formal tests of statistical significance could be performed for OS in the IC1/2/3 or all comer populations, and results of those analyses would be considered exploratory.
Posledično niso mogli izvesti formalnih testov statistične značilnosti za celokupno preživetje v populacijah IC1/2/3 in neselekcioniranih bolnikov, te rezultate smatramo kot raziskovalne.
Your doctor will keep giving you Tecentriq until you no longer benefit from it.
Zdravnik vam bo zdravilo Tecentriq dajal, vse dokler vam bo koristilo.
In the IMpassion130 study, of the 614 patients tested, 89 (15%) carried pathogenic BRCA1/2 mutations.
V študiji IMpassion130 je imelo od 614 testiranih bolnikov 89 (15 %) patogene mutacije BRCA1/2.
Reminder to educate patients/caregivers about the symptoms of immune-related adverse reactions and of the need to report them immediately to the physician.
Opomnik za izobraževanje bolnikov/skrbnikov o simptomih imunsko pogojenih neželenih učinkov in o nujnosti njihovega takojšnjega poročanja zdravniku.
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and bilirubin should be monitored prior to initiation of treatment, periodically during treatment with atezolizumab and as indicated based on clinical evaluation.
Vrednosti aspartat-aminotransferaze (AST), alanin-aminotransferaze (ALT) in bilirubina je treba spremljati pred začetkom zdravljenja z atezolizumabom, redno med zdravljenjem in kot je potrebno glede na klinično oceno.
* An analysis of OS in the all comer population was performed based on the stratified log-rank test and the result is provided for descriptive purposes only (p = 0.0378); according to the pre-specified analysis hierarchy, the p-value for the OS analysis in the all comer population cannot be considered statistically significant.
* Analizo celokupnega preživetja v populaciji neselekcioniranih bolnikov so izvedli na osnovi stratificiranega testa log-rang; rezultat je predviden le za opisne namene (p = 0,0378); v skladu s predhodno določeno hierarhijo analiz, p-vrednosti za analizo celokupnega preživetja v populaciji neselekcioniranih bolnikov ne moremo smatrati za statistično značilno.
• pain in the muscles and bones
• bolečine v mišicah in kosteh
Unstratified HR for other exploratory subgroups.
Nestratificirano razmerje ogroženosti za druge raziskovalne podskupine.
Patient demographics and baseline tumour disease in patients with PD-L1 expression ≥1% were generally representative of the broader study population.
Demografija in izhodiščna tumorska bolezen pri bolnikih z izražanjem PD-L1 ≥ 1 % sta bili na splošno reprezentativni za širšo raziskovano populacijo.
Tecentriq is used to treat adults with:
Tecentriq uporabljamo za zdravljenje odraslih z:
Based on the stratified log-rank test.
na osnovi stratificiranega testa log-rang
By attaching to the protein, Tecentriq helps your immune system to fight your cancer.
Z vezavo na to beljakovino zdravilo Tecentriq vašemu imunskemu sistemu pomaga premagovati raka.
A population pharmacokinetic analysis indicates that the clearance of atezolizumab is 0.200 L/day and the typical terminal elimination half-life is 27 days.
Populacijska farmakokinetična analiza kaže, da je očistek atezolizumaba 0,200 l/dan in da je tipični končni razpolovni čas izločanja 27 dni.
Do not stop treatment with Tecentriq unless you have discussed this with your doctor.
Ne prenehajte zdravljenja z zdravilom Tecentriq, ne da bi se o tem posvetovali z zdravnikom.
• allergic reaction (infusion-related reaction, hypersensitivity or anaphylaxis)
• alergijska reakcija (z infundiranjem povezana reakcija, preobčutljivost ali anafilaksija)
Treatment beyond disease progression was permitted at the discretion of the physician.
Zdravljenje po napredovanju bolezni je bilo dovoljeno po presoji zdravnika.
Patients, including those with EGFR mutations or ALK rearrangements, were enrolled and were randomised in a 2:1 ratio to receive one of the treatment regimens described in Table 8.
Bolnike, vključno s tistimi, ki so imeli mutacije EGFR ali preureditve ALK, so vključili in jih v razmerju 2:1 randomizirali na prejemanje ene od shem zdravljenja, opisanih v preglednici 8.
• Information that atezolizumab can cause serious side effects during or after treatment, that need to be treated right away
• Informacije, da lahko atezolizumab med zdravljenjem ali po njem povzroči resne neželene učinke, ki jih je treba zdraviti takoj.
Women of childbearing potential have to use effective contraception during and for 5 months after treatment with atezolizumab.
Ženske v rodni dobi morajo med zdravljenjem in še 5 mesecev po zdravljenju z atezolizumabom uporabljati učinkovito kontracepcijsko zaščito.
Body weight, gender, positive ADA status, albumin levels and tumour burden have a statistically significant, but not clinically relevant effect on atezolizumab pharmacokinetics.
Telesna masa, spol, pozitivno stanje ADA, koncentracija albumina in tumorsko breme imajo statistično značilen učinek na farmakokinetiko atezolizumaba, ki pa ni klinično pomemben.
For instructions on dilution and handling of the medicinal product before administration, see section 6.6.
Za navodila o razredčenju in ravnanju z zdravilom pred dajanjem glejte poglavje 6.6.
At the time of the updated OS analysis, an exploratory PFS analysis was performed as presented in Table 6.
V času posodobljene analize OS je bila izvedena eksploratorna analiza PFS, ki je predstavljena v preglednici 6.
Tecentriq has minor influence on your ability to drive and use machines.
Zdravilo Tecentriq ima blag vpliv na sposobnost vožnje in upravljanja strojev.
The use of systemic corticosteroids or immunosuppressants before starting atezolizumab should be avoided because of their potential interference with the pharmacodynamic activity and efficacy of atezolizumab.
Uporabi sistemskih kortikosteroidov ali imunosupresivov se je pred uvedbo atezolizumaba treba izogibati, ker lahko vplivajo na farmakodinamično aktivnost in učinkovitost atezolizumaba.
Patients with EGFR mutations or ALK rearrangements should have been previously treated with tyrosine kinase inhibitors.
Bolniki z mutacijami EGFR ali preureditvami ALK so morali biti predhodno zdravljeni z zaviralci tirozin kinaze.
Atezolizumab must be permanently discontinued for any Grade 3 immune-related adverse reaction that recurs and for any Grade 4 immune-related adverse reactions, except for endocrinopathies that are controlled with replacement hormones (see sections 4.2 and 4.8).
Atezolizumab je treba trajno prenehati uporabljati pri vseh imunsko pogojenih neželenih učinkih 3. stopnje, ki se ponovijo, in pri vseh imunsko pogojenih neželenih učinkih 4. stopnje, z izjemo endokrinopatij, ki jih je mogoče nadzorovati z nadomestnimi hormoni (glejte poglavji 4.2 in 4.8).
Patients should be monitored for changes in renal function.
Bolnike je treba nadzorovati glede sprememb v delovanju ledvic.
• feeling very tired (fatigue)
• občutek hude utrujenosti (izčrpanost)
The majority of patients had a baseline ECOG performance status of 1 (59%) and PDL1 expression <1% (approximately 52%).
Večina bolnikov je imela izhodiščno stanje zmogljivosti po ECOG 1 (59 %) in izražanje PD-L1 < 1 % (približno 52 %).
• low number of red blood cells, which can cause tiredness and shortness of breath
• majhno število rdečih krvnih celic, ki lahko povzroči utrujenost in težko dihanje
The time to deterioration in other lung cancer symptoms (i.e. cough, dyspnoea, and arm/shoulder pain) as measured by the EORTC QLQ-LC13 was similar between atezolizumab and docetaxel.
Čas do poslabšanja drugih simptomov raka pljuč (tj. kašlja, dispneje in bolečin v roki/rami), merjenih z EORTC QLQ-LC13, je bil z atezolizumabom in docetakselom podoben.
What you need to know before you are given Tecentriq
Kaj morate vedeti, preden boste dobili zdravilo Tecentriq
• prepared in a laminar flow hood or biological safety cabinet using standard precautions for the safe handling of intravenous agents.
• Priprava mora potekati v komori z laminarnim pretokom zraka ali v varnostni komori za pripravo bioloških zdravil; upoštevati je treba standardne previdnostne ukrepe za varno ravnanje z intravenskimi zdravili.
• 840 milligrams (mg) every two weeks, or
• 840 miligramov (mg) na dva tedna ali
Tecentriq must be initiated and supervised by physicians experienced in the treatment of cancer.
Zdravilo Tecentriq morajo uvesti in nadzorovati zdravniki z izkušnjami pri zdravljenju raka.
Your first infusion will be given over 60 minutes.
Prva infuzija, ki jo boste dobili, bo trajala 60 minut.
14.1 (9.2, NE) 15.9 (10.4, NE)
12,3 (6,0; NO) 14,1 (9,2; NO) 15,9 (10,4; NO)
Median duration of PFS (months)
Mediano trajanje PFS (meseci)
Based on exploratory analysis and acknowledging the small sample size, the presence of BRCA1/2 mutation does not seem to impact the PFS clinical benefit of atezolizumab and nab-paclitaxel.
Na podlagi eksploratorne analize in upoštevanja majhne velikosti vzorca se zdi, da prisotnost mutacije BRCA1/2 nima vpliva na klinično korist atezolizumaba in nabpaklitaksela v smislu PFS.
Most patients were women (99.6%), 67.5% were white and 17.8% Asian.
Večina vključenih je bila žensk (99,6 %), 67,5 % je bilo belk in 17,8 % Azijk.
The initial dose of Tecentriq must be administered over 60 minutes.
Začetni odmerek zdravila Tecentriq je treba dati v 60 minutah.
The effect of age on the pharmacokinetics of atezolizumab was assessed in a population pharmacokinetic analysis.
Vpliv starosti na farmakokinetiko atezolizumaba so ocenili v populacijski farmakokinetični analizi.
The demographics and baseline disease characteristics of the study population defined as ITT-WT (n=679) were well balanced between the treatment arms.
Demografske značilnosti in izhodiščne značilnosti bolezni v študijski populaciji, opredeljeni kot populacija ITT-divji tip (n = 679), so bile med terapevtskima skupinama dobro uravnotežene.
Per final analysis for PFS, ORR, DOR and first interim analysis for OS at clinical cut off 17th April 2018
3. po končni analizi PFS, ORR, DOR in prvi vmesni analizi OS na klinični presečni datum 17. april 2018;
PFS, ORR and DOR results of IMpassion130 for patients with PD-L1 expression ≥ 1% at the time of the final analysis for PFS with a median survival follow up of 13 months are summarized in Table 6 with Kaplan-Meier curves for PFS in Figure 4.
Rezultati PFS, ORR in DOR v preskušanju IMpassion130 pri bolnikih z izražanjem PD-L1 ≥ 1 % v času končne analize PFS z medianim spremljanjem preživetja 13 mesecev so povzeti v preglednici 6 in s Kaplan-Meierjevima krivuljama za PFS na sliki 4.
Prior to launch of Tecentriq in each Member State the Marketing Authorisation Holder (MAH) must agree about the content and format of the educational programme, including communication media,
Pred prihodom zdravila Tecentriq na trg v vsaki državi članici se mora imetnik dovoljenja za promet z zdravilom s pristojnim nacionalnim organom dogovoriti glede vsebine in oblike izobraževalnega programa, vključno s sredstvi obveščanja, načini razdeljevanja in vsemi ostalimi vidiki programa.
No dose reduction of atezolizumab was allowed.
Zmanjšanje odmerka atezolizumaba ni bilo dovoljeno.
• Evidence of clinical benefit as assessed by the investigator
• dokazi o klinični koristi po oceni raziskovalca.
51% of patients' tumours had PD-L1 expression of ≥ 1% TC or ≥ 1% IC and 49% of patients' tumours had PD-L1 expression of < 1% TC and < 1% IC.
51 % tumorjev bolnikov je izražalo PD-L1 na ≥ 1 % TC ali ≥ 1% IC in 49 % tumorjev bolnikov je izražalo PD-L1 na < 1 % TC in < 1 % IC.
NE (11.1, NE)
NO (11,1; NO)
Median duration of treatment was 15.0 weeks and median duration of survival follow-up was 8.5 months in all comers.
Mediano trajanje zdravljenja je bilo 15,0 tednov; mediano trajanje spremljanja preživetja je bilo 8,5 meseca pri neselekcioniranih bolnikih.
Adverse reactions known to occur with atezolizumab or chemotherapies given alone may occur during treatment with these medicinal products in combination, even if these reactions were not reported in clinical trials with combination therapy.
Znani neželeni učinki samostojnega zdravljenja z atezolizumabom ali kemoterapijami se lahko pojavijo pri kombiniranem zdravljenju s temi zdravili, čeprav o njih v kliničnih preskušanjih s kombiniranim zdravljenjem niso poročali.
Median OS for all patient subgroups (PD-L1 expression ≥ 5 % and ≥ 1 %) and in all comers was 10.6 months.
Mediano celokupno preživetje za vse podskupine bolnikov (izražanje PD-L1 ≥ 5 % in ≥ 1 %) in za neselekcionirane bolnike je bilo 10,6 meseca.
Other medicines and Tecentriq
Druga zdravila in zdravilo Tecentriq
No data are available in patients with either moderate or severe hepatic impairment.
Podatkov o bolnikih z zmerno ali hudo okvaro jeter ni na voljo.
Please also refer to the full prescribing information for the combination products (see also section 5.1).
Glejte tudi celotne informacije za predpisovanje zdravil, ki se uporabljajo v kombinaciji (glejte tudi poglavje 5.1).
The time to deterioration (a sustained ≥ 10-point decline from baseline score) of patient-reported global health status/health-related quality of life as measured by the EORTC QLQ-C30 was similar in each treatment group indicating that all patients maintained their baseline HRQoL for a comparable duration of time.
Čas do poslabšanja (trajno zmanjšanje ≥ 10 točk glede na izhodiščno vrednost) celotnega zdravstvenega stanja/zdravstvene kakovosti življenja po navedbi bolnikov, merjen z EORTC QLQC30, je bil v obeh zdravljenih skupinah podoben, kar kaže, da so vsi bolniki ohranili izhodiščno zdravstveno kakovost življenja v primerljivem časovnem obdobju.
The majority of patients were white (72.1%), 53.9% of patients within the chemotherapy arm received vinflunine, 71.4% of patients had at least one poor prognostic risk factor and 28.8% had liver metastases at baseline.
Večina bolnikov je bila belcev (72,1 %), 53,9 % bolnikov v skupini s kemoterapijo je prejemalo vinflunin, 71,4 % bolnikov je imelo vsaj eno slab napovedni dejavnik tveganja in 28,8 % jih je ob začetku zdravljenja imelo zasevke v jetrih.
The maximum systemic accumulation ratio across dosing regimens is 3.3.
Maksimalni delež sistemskega kopičenja obeh režimov odmerjanja je bil 3,3.
There were no effects on the male reproductive organs.
Vplivov na reproduktivne organe samcev ni bilo.
Dose reductions of Tecentriq are not recommended.
Odmerkov zdravila Tecentriq ni priporočljivo zmanjševati.
However, patients who had prior anti-CTLA-4 treatment could be enrolled, as long as the last dose was received at least 6 weeks prior to randomization, and there was no history of severe immunerelated adverse effects from anti-CTLA-4 (NCI CTCAE Grades 3 and 4).
Vključeni pa so bili lahko bolniki, ki so predhodno prejemali zdravila proti CTLA-4, če so zadnji odmerek takšnega zdravila prejeli vsaj 6 tednov pred randomizacijo in v anamnezi niso imeli hudih imunsko pogojenih neželenih učinkov (stopnje 3. oz. 4. po NCI CTCAE) takšnega zdravljenja.
Of the 62 patients, two experienced a fatal event.
Pri dveh od teh 62 bolnikov se je končal s smrtjo.
Based on population PK and exposure-response analyses age (21-89 years), region, ethnicity, renal impairment, mild hepatic impairment, level of PD-L1 expression, or ECOG performance status have no effect on atezolizumab pharmacokinetics.
Populacijska farmakokinetika in analize izpostavljenost-odziv kažejo, da starost (21-89 let), regija, etnična pripadnost, okvara ledvic, blaga okvara jeter, raven izražanja PD-L1 ali stanje zmogljivosti po ECOG nimajo vpliva na farmakokinetiko atezolizumaba.
Patients who had prior treatment with CD137 agonists or immune checkpoint blockade therapies (anti-PD-1, and anti-PD-L1 therapeutic antibodies) were not eligible.
Bolniki, predhodno zdravljeni z agonisti CD137 ali zaviralci imunskih kontrolnih točk (zdravili proti PD-1 in terapevtskimi protitelesi proti PD-L1), niso bili primerni za vključitev.
The safety of atezolizumab as monotherapy is based on pooled data in 3,178 patients across multiple tumour types.
Informacije o varnosti atezolizumaba v monoterapiji temeljijo na združenih podatkih 3178 bolnikov z različnimi vrstami tumorjev.
Weekly administration of atezolizumab to female monkeys at an estimated AUC approximately 6 times the AUC in patients receiving the recommended dose caused an irregular menstrual cycle pattern and a lack of newly formed corpora lutea in the ovaries which were reversible.
Tedenska uporaba atezolizumaba pri opičjih samicah pri ocenjeni AUC, ki je bila približno 6-krat večja od AUC pri bolnikih, ki so prejemali priporočen odmerek, je povzročila nereden vzorec menstruacijskega ciklusa in odsotnost novonastalih rumenih telesc v jajčnikih, ki sta bila reverzibilna.
The effect of severe renal impairment on the pharmacokinetics of atezolizumab is unknown.
Učinek hude okvare ledvic na farmakokinetiko atezolizumaba ni znan.
• elevated liver enzymes (shown in tests), which may be a sign of an inflamed liver
• zvišanje jetrnih encimov (pokaže se na preiskavah krvi), ki je lahko znak vnetja jeter
Patients were treated until loss of clinical benefit as assessed by the investigator or unacceptable toxicity.
Bolnike so zdravili do izgube klinične koristi po oceni raziskovalca ali do nesprejemljive toksičnosti.
Hypothyroidism or hyperthyroidism
Hipotiroidizem ali hipertiroidizem
Patients were randomised (1:1) to receive either atezolizumab or chemotherapy.
Bolniki so bili randomizirani (1:1) na prejemanje atezolizumaba ali kemoterapije.
The PFS, ORR and DOR results from the primary analysis as well as the exploratory OS final analysis results are summarized in Table 12.
Rezultati PFS, ORR in DOR iz primarne analize in rezultati eksploratorne končne analize OS so povzeti v preglednici 12.
• inflammation of the mouth or lips
• vnetje ust ali ustnic
Comparisons with respect to OS between the treatment arm and control arm within the IC2/3, IC1/2/3, and ITT (Intention-to-treat, i.e. all comers) populations were tested using a hierarchical fixed-sequence procedure based on a stratified log-rank test at two-sided level of 5% as follows: step 1) IC2/3 population; step 2) IC1/2/3 population; step 3) all comers population.
Primerjave celokupnega preživetja med zdravljeno in kontrolno skupino znotraj populacije IC2/3, IC1/2/3 in ITT (intention-to-treat; z namenom zdraviti, tj. vsi neselekcionirani bolniki) so testirali z uporabo hierarhičnega postopka s fiksnim zaporedjem glede na stratificiran dvostranski 5-% test log-rang, kot sledi: korak 1): populacija IC2/3; korak 2) populacija IC1/2/3; korak 3) vsi neselekcionirani bolniki.
Docetaxel (n = 425)
docetaksel (n = 425)
OS results were similar for patients aged < 65 and ≥ 65 subgroups, respectively.
Rezultati OS so bili podobni pri bolnikih, starih < 65 let, in pri bolnikih, starih ≥ 65 let.
The primary efficacy endpoint for IMvigor211 is overall survival (OS).
Primarni opazovani dogodek učinkovitosti za IMvigor211 je celokupno preživetje (OS, overall survival).
• Reminder to carry the Patient Alert Card at all times and to show it to all healthcare professionals that may treat them.
• Opomnik, naj imajo bolniki opozorilno kartico za bolnika vedno pri sebi in jo pokažejo vsem zdravstvenim delavcem, ki jih zdravijo.
All prescribers of Tecentriq must be familiar with the Physician Information and Management Guidelines.
Vsi zdravniki, ki predpisujejo zdravilo Tecentriq, morajo biti dobro seznanjeni z Informacijami za zdravnika in Smernicami za vodenje bolnikov.
The majority of patients were male (65%), white (80%), and 9% had brain metastases and most patients were current or previous smokers (97%).
Večina bolnikov je bila moških (65 %), belcev (80 %), 9 % jih je imelo zasevke v možganih in večina bolnikov je bila sedanjih ali nekdanjih kadilcev (97 %).
The schedule of administration must be adjusted to maintain the appropriate interval between doses.
Urnik dajanja zdravila je treba nato prilagoditi ustreznemu presledku med odmerki.
The baseline and prognostic disease characteristics of the IMvigor210 Cohort 1 study population were overall comparable to patients in the clinic who would be considered cisplatin ineligible but would be eligible for a carboplatin-based combination chemotherapy.
Izhodiščne in prognostične značilnosti bolezni 1. kohorte študijske populacije IMvigor210 so bile na splošno primerljive z značilnostmi bolnikov, ki niso bili primerni za zdravljenje s cisplatinom, vendar pa bi bili primerni za kombinirano kemoterapijo na osnovi karboplatina.
If a planned dose of Tecentriq is missed, it should be administered as soon as possible.
V primeru izpuščenega načrtovanega odmerka zdravila Tecentriq je treba odmerek dati čim prej.
The iDMC did not recommend any change of therapy for patients who had already been randomized to and were receiving treatment in the monotherapy arm. No other changes were recommended.
Odbor iDMC ni priporočil spremembe zdravljenja za bolnike, ki so že bili randomizirani v skupino z monoterapijo in so zdravljenje že začeli prejemati.
• inflammation of the heart muscle
• vnetje srčne mišice
You will be given Tecentriq by a doctor experienced in cancer treatment in a hospital or clinic.
Zdravilo Tecentriq vam bo dal zdravnik z izkušnjami pri zdravljenju raka v bolnišnici ali ambulanti.
Programmed death-ligand 1 (PD-L1) may be expressed on tumour cells and/or tumour-infiltrating immune cells, and can contribute to the inhibition of the antitumour immune response in the tumour microenvironment.
Ligand za programirano celično smrt 1 (PD-L1) je lahko izražen na tumorskih celicah in/ali celicah imunskega sistema, ki infiltrirajo tumor, in lahko pripomore k zavrtju protitumorskega imunskega odziva v mikrookolju tumorja.
You must not be given Tecentriq if:
Zdravila Tecentriq ne smete dobiti:
Tell your doctor straight away if you notice any of the side effects below or if they get worse.
Zdravnika morate takoj obvestiti, če opazite katerega od spodaj navedenih neželenih učinkov ali če se kakšen neželen učinek poslabša.
The key results of this study with a median survival follow-up of 21 months are summarised in Table 10.
Ključni rezultati te študije z medianim spremljanjem preživetja 21 mesecev so povzeti v preglednici 10.
Tecentriq works by attaching to a specific protein in your body called programmed death-ligand 1 (PD-L1).
Zdravilo Tecentriq deluje tako, da se v telesu veže na specifično beljakovino, imenovano ligand za programirano celično smrt 1 (PD-L1).
• Stop your treatment with Tecentriq.
• konča vaše zdravljenje z zdravilom Tecentriq.
• performed under aseptic conditions by trained personnel in accordance with good practice rules especially with respect to the aseptic preparation of parenteral products.
• Pripravo mora izvesti usposobljeno osebje v aseptičnih pogojih v skladu s pravili dobre prakse,
Tecentriq will be stored by the healthcare professionals at the hospital or clinic.
Shranjevanje zdravila Tecentriq Zdravilo Tecentriq bodo shranjevali zdravstveni delavci v bolnišnici ali ambulanti.
• nerve damage resulting in possible numbness, pain, and/or loss of motor function (peripheral neuropathy)
• okvara živcev, ki ima lahko za posledico omrtvičenost, bolečine in/ali poslabšanje zmožnosti gibanja (periferna nevropatija)
NE (14.1, NE)
NO (14,1; NO)
The key results are summarised in Table 9 and Kaplan-Meier curves for OS and PFS are presented in Figures 6 and 8, respectively.
Ključni rezultati so povzeti v preglednici 9; Kaplan-Meierjevi krivulji OS in PFS sta prikazani na slikah 6 in 8.
An updated OS analysis was performed with a median follow up of 18 months, OS results are presented in Table 6 and Kaplan-Meier curves in Figure 5.
Posodobljena analiza celokupnega preživetja je bila narejena z mediano 18-mesečnim spremljanjem; rezultati OS so prikazani v preglednici 6 in s Kaplan-Meierjevima krivuljama na sliki 5.
Ask your doctor if you should stop breast-feeding or if you should stop treatment with Tecentriq.
Z zdravnikom se posvetujte, ali nehate dojiti ali nehate z zdravljenjem z zdravilom Tecentriq.
Includes reports of encephalitis, meningitis, photophobia.
Vključuje poročila o encefalitisu, meningitisu, fotofobiji.